A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer Clinical Trial

Official title:

A Phase II Study of Neoadjuvant Double-drug Chemotherapy With Platinum Plus Anlotinib Hydrochloride in Stage III(N2) Non-small-cell Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04181372
• Other study ID #: NSCLC 001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 2019
• Est. completion date: August 1, 2022

Study information

• Verified date: November 2019
• Source: The First Affiliated Hospital of Guangzhou Medical University
• Contact: Jiexia Zhang, prof.
• Phone: +8613903056432
• Email: drzjxcn[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant double-drug chemotherapy containing platinum plus anlotinib hydrochloride in patients with stage III(N2) non-small-cell lung cancer.

Description:

This is a prospective, open-label, multi-institutional, positive medicine control of equal rank comparative study of neoadjuvant double-drug chemotherapy with platinum plus anlotinib hydrochloride in stage III(N2) non-small-cell lung cancer.The main purpose of this study was to compare the difference in N2 downgrade rate of lymph node and resectability rate between the experimental and control groups, to evaluate the efficacy of anlotinib hydrochloride, and to observe and evaluate its objective response rate(ORR)，Disease-free Survival (DFS)and overall survival(OS).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: August 1, 2022
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age :18 Years to 75 Years (Adult, Older Adult)

2. Pathological diagnosis with Stage III-N2 NSCLC which is clinically resectable and the N2 is diagnosed by either mediastinoscopy,EBUS,PET/CT;

3. EGFR?ALK?ROS1 mutation-negative;Patients with squamous cell carcinoma may not have genetic testing;PD-L1<5%;

4. According to the RECIST 1.1 standard, there is at least one measurable target lesion;

5. ECOG physical score 0-1 points; expected survival time = 3 months;

6. The main organ function meets the following criteria:1)blood routine: absolute value of neutrophils = 1.5 × 109 / L, platelets = 75 × 109 / L, hemoglobin = 80 g / L;2)Blood biochemistry: total bilirubin = 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase = 2.5 times the upper limit of normal value (if liver metastasis, = upper limit of normal value 5 times), serum creatinine = 1.5 times the upper limit of normal;

7. Subjects voluntarily joined the study and signed informed consent, with good adherence and follow-up.

Exclusion Criteria:

1. Stage I, II , IV orNSCLC;

2. Small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer);central lung squamous carcinoma along with cavum;

3. Patients with contraindication of chemotherapy

4. Subjects who have previously used Anlotinib;

5. Systematic anti-tumor treatments have been performed for the past 2 weeks, including chemotherapy, radiotherapy (except for metastatic lesions other than thoracic radiation), targeted therapy, immunotherapy, and biotherapy;

6. Imaging (CT or MRI) shows that the distance between tumor lesion and the large blood vessel is = 5 mm, or there is a central tumor that invades the local large blood vessel; or there is a significant pulmonary cavity or necrotizing tumor;

7. A history of active bleeding within the first 6 months of screening, or receiving thrombolysis or anticoagulant therapy, or the investigator believes that there is a clear tendency to gastrointestinal bleeding (such as esophageal varices with bleeding risk, local activity) Ulcer lesions, etc.) or active hemoptysis;

8. A thrombotic event occurs within 6 months (including arteriovenous thrombosis, pulmonary embolism, cerebrovascular accident, including transient ischemic attack, etc.);

9. Cardiac diseases with obvious clinical symptoms, such as: congestive heart failure, coronary heart disease with obvious symptoms, arrhythmia with difficult drug control (including clinically significant QTc interval prolongation history, or screening period QTc interval women >470ms, Male > 450ms), had myocardial infarction within 6 months, or cardiac insufficiency;

10. Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure = 160 mmHg, or diastolic blood pressure = 100 mmHg;

11. Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy;

12. Surgery (<28 days) before the study was selected or the surgical incision did not completely heal, or there were other unhealed wounds;

13. Active or uncontrolled serious infections;

14. Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures;

15. Increasing the risk associated with participating in a study or study drug, and at the discretion of the investigator, may lead to other conditions in which the patient is not eligible for inclusion in the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Stage III Non-small-cell Lung Cancer

Intervention

Drug:
• Anlotinib hydrochloride
Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
• platinum-based chemotherapy medicine
(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lymph node(N2)downstage rate	Lymph node downstage rate is depended on the image or pathology dignosis after surgery,staging from N2 to N1 / N0.	3 months
Secondary	Objective Response Rate (ORR)	ORR is the number of participants with a Complete Response (CR) and Partial Response (PR) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared to baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions.	3 months
Secondary	Resectability rate	Resectability rate was defined as the percentage of patients who were able to undergo surgery after neoadjuvant therapy.	Lymph node downstage rate is depended on the pathology dignosis after surgery, an expected average of 8 weeks from randomization.
Secondary	Pathological complete response (pCR) rate	Pathologic Complete Response Rate is defined as lack of evidence of viable cancer in the surgical specimen at the time of surgery.	3 months
Secondary	Disease-free Survival (DFS)	The period after curative treatment [disease eliminated] when no disease can be detected.From date of randomization until the date of first documented progression, whichever came first, assessed up to 40 months.	Every 3 months.
Secondary	Overall Survival (OS)	OS was assessed from randomization to death as a result of any cause.	3 years
Secondary	adverse events(AEs)	Number of participants with perioperative complications.	3 months